1. Home
  2. EARN vs CRGX Comparison

EARN vs CRGX Comparison

Compare EARN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • CRGX
  • Stock Information
  • Founded
  • EARN 2012
  • CRGX 2021
  • Country
  • EARN United States
  • CRGX United States
  • Employees
  • EARN N/A
  • CRGX N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • CRGX
  • Sector
  • EARN Real Estate
  • CRGX
  • Exchange
  • EARN Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • EARN 213.3M
  • CRGX 190.0M
  • IPO Year
  • EARN 2013
  • CRGX 2023
  • Fundamental
  • Price
  • EARN $5.92
  • CRGX $4.59
  • Analyst Decision
  • EARN Buy
  • CRGX Hold
  • Analyst Count
  • EARN 2
  • CRGX 7
  • Target Price
  • EARN $6.00
  • CRGX $5.33
  • AVG Volume (30 Days)
  • EARN 230.9K
  • CRGX 1.9M
  • Earning Date
  • EARN 08-11-2025
  • CRGX 08-11-2025
  • Dividend Yield
  • EARN 16.16%
  • CRGX N/A
  • EPS Growth
  • EARN N/A
  • CRGX N/A
  • EPS
  • EARN N/A
  • CRGX N/A
  • Revenue
  • EARN $35,893,000.00
  • CRGX N/A
  • Revenue This Year
  • EARN $3.21
  • CRGX $57.81
  • Revenue Next Year
  • EARN $18.63
  • CRGX N/A
  • P/E Ratio
  • EARN N/A
  • CRGX N/A
  • Revenue Growth
  • EARN 43.30
  • CRGX N/A
  • 52 Week Low
  • EARN $4.33
  • CRGX $3.00
  • 52 Week High
  • EARN $7.20
  • CRGX $25.45
  • Technical
  • Relative Strength Index (RSI)
  • EARN 64.84
  • CRGX 61.56
  • Support Level
  • EARN $5.71
  • CRGX $4.32
  • Resistance Level
  • EARN $5.79
  • CRGX $4.63
  • Average True Range (ATR)
  • EARN 0.06
  • CRGX 0.16
  • MACD
  • EARN 0.01
  • CRGX 0.04
  • Stochastic Oscillator
  • EARN 82.14
  • CRGX 76.44

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

Share on Social Networks: